Oncoinvent (ONCIN) Investor presentation summary

Transforming cancer care through direct alpha therapy

• Focus on direct alpha therapy to address peritoneal metastases in cancer care.

• RadspherinⓇ offers a non-biological, receptor-independent approach using alpha emitters.

• Developed by a team with a strong track record in radiopharmaceutical innovation.

Unmet medical need in peritoneal metastases

• Peritoneal metastases are common in ovarian and colorectal cancers, with high relapse rates after surgery.

• Up to 85% of ovarian cancer patients relapse post-surgery, with recurrences mainly in the peritoneum.

• Current curative options are limited to surgery, which often leaves behind micrometastases.

RadspherinⓇ treatment concept and administration

• Combines alpha-emitting 224Ra with CaCO3 microparticles for targeted peritoneal therapy.

• Delivers 75% of the radiation dose in the first week, with an 8-day shelf life for centralized manufacturing.

• Administered 1–3 days post-surgery via indwelling catheter, maximizing local effect and minimizing systemic toxicity.